CLINICAL TRIALS PROFILE FOR MEDROL ACETATE

All Clinical Trials for MEDROL ACETATE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT04515966 ↗	A Comparison of Ultrasound-guided Steroid Injection With Wrist Splint in Carpal Tunnel Syndrome	Recruiting	Mercy Health Ohio	Phase 4	2020-12-01	Carpal Tunnel Syndrome (CTS) is caused by compression of a nerve called the median nerve as it travels through a narrow tunnel within the wrist on its way to the hand. Compression of the median nerve causes numbness, tingling, pain and weakness of the hand and fingers. CTS is usually treated with rest or a change in the activity level. It can also be treated with a splint that limits bending of the hand and wrist. Other treatments include a steroid injection near the median nerve. Surgery can be performed if the symptoms are severe or persistent. Compression of the median nerve can cause swelling that may be observed with ultrasound of the wrist. Ultrasound can also be used to help guide the needle to inject the steroid solution in close proximity to the median nerve while avoiding injury to the nerve. The investigators plan to compare the effectiveness of a splint and an ultrasound-guided steroid injection in the treatment of mild to moderate CTS. Individuals with CTS who agree to participate, will be randomly assigned to two groups. One group will be treated with a splint and the other with a steroid injection performed under ultrasound guidance. The severity of CTS symptoms will be determined prior to beginning the study and also at 6 weeks, 3 months, 6 months and 1 year following each of the two treatment interventions. The median nerve size (diameter) will be measured in all participants prior to beginning the study and also following both treatment interventions at 6 weeks, 3 months, 6 months and 1 year. At the conclusion of the study, the investigators will determine which of the two treatments, splint or steroid injection, is more effective in alleviating CTS symptoms. The investigators will also determine if either or both treatments result in a change in swelling of the median nerve as measured by ultrasound.
NCT04757740 ↗	Comparison Between Platelet-rich Fibrin and Steroid for Intra-articular Injection for Sacroiliac Joint Dysfunction	Recruiting	Fayoum University Hospital	Phase 4	2021-03-01	Low back pain is one of the commonest complaints nowadays affecting nearly 20% of the population, Sacroiliac joint has been accused of being the primary cause of pain in about 10%: 27% of this population. The sure diagnosis of sacroiliac joint pain is challenging because of multiple crossed factors of facet joint pain and intervertebral disc pain. Diagnosis can be done by history taking, local examination, imaging techniques, and controlled local anesthetic blocks. Controlled local anesthetic blocks are diagnostic and therapeutic done by various methods either landmark-guided or imaging-assisted either by fluoroscopy, computed tomography (CT), magnetic resonance (MRI), or ultrasound-guided. Lower cost, real-time viewing of needle leading to higher accuracy rate, and low ionizing radiation dose are favoring ultrasound-guided injection over other modalities. Numerous treatment modalities are being used for sacroiliac joint pain ranging from physiotherapy and systemic analgesics like Non-steroidal anti-inflammatory drugs (NSAIDs) to minimally invasive intra-articular, periarticular injection, radiofrequency neurotomy, and surgical fusion of the joint. Multiple injectates are being used for intraarticular injection most commonly local anesthetics and steroids which offer short-term symptomatic relief and delay the degenerative process. The need for a longer duration effect directly affects the disease process itself aiming for accelerating the joint healing rate by biological growth factors found in human blood especially in platelets. Platelet-rich plasma (PRP) has been used aiming to inject a high concentration of growth factors directly into the joint. Platelet-rich fibrin (PRF), the second generation of platelet-rich plasma is now tried having the advantage of a simpler preparation and higher values of growth factors.

Clinical Trial Conditions for MEDROL ACETATE

Condition Name

Condition Name for MEDROL ACETATE
Intervention	Trials
Carpal Tunnel Syndrome	1
Low Back Pain	1

Condition MeSH

Condition MeSH for MEDROL ACETATE
Intervention	Trials
Carpal Tunnel Syndrome	1
Low Back Pain	1
Joint Diseases	1

Clinical Trial Locations for MEDROL ACETATE

Trials by Country

Trials by Country for MEDROL ACETATE
Location	Trials
United States	1
Egypt	1

Trials by US State

Trials by US State for MEDROL ACETATE
Location	Trials
Ohio	1

Clinical Trial Progress for MEDROL ACETATE

Clinical Trial Phase

Clinical Trial Phase for MEDROL ACETATE
Clinical Trial Phase	Trials
Phase 4	2

Clinical Trial Status

Clinical Trial Status for MEDROL ACETATE
Clinical Trial Phase	Trials
Recruiting	2

Clinical Trial Sponsors for MEDROL ACETATE

Sponsor Name

Sponsor Name for MEDROL ACETATE
Sponsor	Trials
Mercy Health Ohio	1
Fayoum University Hospital	1

Sponsor Type

Sponsor Type for MEDROL ACETATE
Sponsor	Trials
Other	2

Last updated: May 3, 2026

MEDROL ACETATE: Clinical Trials Update, Market Analysis, and Projection

Medrol Acetate is the brand name for methylprednisolone acetate, a systemic corticosteroid administered by injection (commonly intra-articular, intramuscular, and periarticular use across labels and formularies depending on country). Market access, uptake, and pricing are driven by: (1) chronic corticosteroid demand, (2) physician preference and intra-articular utilization patterns, (3) generic penetration, and (4) reimbursement and tender dynamics for steroid injectables.

This brief compiles a clinical-trials status view and a market projection framework for methylprednisolone acetate (Medrol Acetate) and its market context.

---

What clinical trials landscape exists for Medrol Acetate today?

Trial activity: what is observable

Public registries consistently show that methylprednisolone acetate is used in trials as:

• Background standard-of-care steroid in inflammatory/orthopedic protocols
• Comparator arm versus other corticosteroid formulations
• Concomitant therapy in procedures (e.g., joint injections), typically without new long-cycle development

For a branded, off-patent steroid injectable class, registries tend to skew toward:

• Small-to-moderate interventional studies
• Studies comparing formulation, dosing regimen, or administration technique
• Real-world utilization studies or pragmatic designs
• Secondary endpoints rather than disease-modifying outcomes

Implication for pipeline value: in most jurisdictions, methylprednisolone acetate is treated as mature product economics, where incremental value comes from formulation differentiation in practice, procurement dynamics, and line extensions, not from novel mechanisms.

Design patterns seen in registered studies

Across methylprednisolone acetate-associated research, common endpoints include:

• Pain and function score changes (e.g., WOMAC-type scales for osteoarthritis)
• Imaging or clinical inflammation markers where applicable
• Time-to-relief and duration of effect
• Safety signals focused on injection-related adverse events and systemic steroid effects (glucose, blood pressure, infection risk)

Practical clinical positioning

Methylprednisolone acetate is typically positioned for:

• Inflammatory joint conditions
• Acute flare management
• Procedure-adjunct inflammation control

Because it is an established corticosteroid, trial announcements and registry updates tend to be less frequent than for new chemical entities, and more frequent for comparative or regimen-optimization studies.

---

Where does Medrol Acetate sit in the market?

Market drivers

1. High baseline demand for corticosteroid injections
   Joint and soft tissue inflammation remain large-volume indications across primary care, rheumatology, orthopedics, sports medicine, and pain management.

2. Generic-led pricing pressure
   Most corticosteroid injectables face sustained generic competition. Brand performance depends on:

   • Contracting and tender outcomes
   • Hospital formulary acceptance
   • Supply continuity
   • Packaging and dosing convenience

3. Reimbursement and procurement behavior Tender systems often select based on lowest effective price plus supply reliability. Clinical practice guidelines typically support steroid injections broadly, which sustains volume even as price declines.

4. Safety-driven clinician selection Steroid injection usage depends on physician risk tolerance and patient profile. Systems that restrict repeated dosing or require specific monitoring can affect utilization patterns.

Competitive set (market context)

Medrol Acetate competes in a broader injectable corticosteroid environment that includes:

• Alternative steroid injectables (other depot corticosteroids and solutions)
• Different formulations designed to alter duration of effect or reduce injection frequency (where available)
• Generic methylprednisolone acetate equivalents in many markets

The practical competitive axis is procurement price plus expected clinical duration, not innovation.

---

How will the market evolve: 2026-2031 projection

Projection approach

Because methylprednisolone acetate is an established, off-patent corticosteroid, the forecast should be built on:

• Unit demand: driven by procedure frequency and guideline-supported usage
• Price: driven by generic intensity and contracting
• Mix: location-based differences in brand vs generic penetration
• Regulatory and supply: limited upside unless there is supply disruption for competitors or market access gains

5-year outlook (base case)

Below is a projection framework expressed in directional terms suitable for investment and R&D planning. It assumes continued generic competition and stable clinical use.

Metric	2026-2031 base case direction	Key reason
Global demand (units)	Stable to low growth	Ongoing steroid injection need for inflammatory conditions
Global sales value	Flat to modest decline	Continued price erosion from generics and tenders
Share of brand vs generic	Declines or stabilizes	Brand premium squeezed by procurement norms
New clinical differentiation	Limited	Incremental trials concentrate on regimen optimization vs novel mechanisms
Volatility	Moderate	Tender cycles and supply continuity drive quarter-to-quarter variation

Scenario view

Scenario	Demand	Price	Value	What drives it
Upside	Up	Stable	Up	Favorable contracting, supply constraints for competitors, brand retention
Base	Flat	Down	Flat to down	Generic pressure continues; no major label expansion
Downside	Down	Down	Down	Tender wins for cheaper competitors, restricted formularies, supply disruptions impacting continuity

---

What matters for near-term commercialization and lifecycle strategy?

Commercial levers that actually move results

1. Hospital and tender contracting

   • Maintain formulary status
   • Reduce stockouts and lead time variability
   • Provide reliable packaging and dosing availability

2. Segmentation by administration use-case

   • Intra-articular workflows
   • Periarticular pain protocols
   • Procedure-adjunct care pathways

3. Pharmacovigilance and safety communications

   • Minimize reputational drag from systemic steroid risks
   • Ensure consistent risk communication aligned to label requirements

4. Regulatory hygiene

   • Keep local variations compliant (labeling, storage, administration instructions)
   • Avoid disruptions in batch release

R&D posture: where additional trials can create value

For mature depot corticosteroids, R&D that creates measurable business value typically targets:

• Administration technique optimization (less frequent dosing intervals, training protocols)
• Comparative effectiveness versus other steroid depots in defined populations
• Safety and tolerability improvements tied to injection protocols
• Real-world evidence in high-volume care settings to support formulary retention

---

Key Takeaways

• Medrol Acetate (methylprednisolone acetate) is a mature systemic corticosteroid injectable where trial activity is usually comparative, regimen-focused, or pragmatic, not mechanism-changing.
• Market value is price-led due to generic competition; unit demand is steadier because steroid injections remain standard for inflammatory conditions.
• 2026-2031 outlook is best modeled as stable units with flat-to-declining sales value under base-case generic and tender dynamics.
• Near-term commercial performance depends most on formulary/tender outcomes, supply continuity, and protocol adoption, rather than new clinical breakthroughs.

---

FAQs

1. Is Medrol Acetate in late-stage development?
   No. The product class is mature; registered studies typically support regimen, comparative, or real-world positioning rather than late-stage mechanism innovation.

2. What drives Medrol Acetate sales most: demand or price?
   Price. Generic penetration and tender contracting typically drive value contraction even when unit demand remains stable.

3. What patient populations use methylprednisolone acetate most often?
   Patients with inflammatory joint and soft tissue conditions where depot corticosteroid injection is consistent with clinical practice patterns (often osteoarthritis flares and other joint inflammation contexts).

4. Can new trials materially increase market share for a branded steroid?
   Only if they translate into formulary adoption advantages, tighter dosing protocols, or compelling comparative outcomes that procurement committees adopt.

5. What is the most realistic growth lever between 2026 and 2031?
   Contracting and mix management (brand retention in institutional accounts), plus protocol standardization that increases injection frequency or reduces substitution to lower-cost alternatives.

---

References

[1] U.S. National Library of Medicine. ClinicalTrials.gov. https://clinicaltrials.gov/
[2] European Medicines Agency (EMA). EPAR and medicine information for corticosteroids and methylprednisolone products. https://www.ema.europa.eu/
[3] U.S. Food and Drug Administration (FDA). Drug Approval Reports and product labeling resources. https://www.fda.gov/
[4] World Health Organization. WHO Model List of Essential Medicines: corticosteroids (systemic). https://www.who.int/